Molecule News and Research

RSS

Corkscrew structure inspires new weapon against E-coli and MRSA

Scientists at the University of Warwick have taken inspiration from corkscrew structures found in nature to develop a new weapon in the fight against infections like E-coli and MRSA.

28 Nov 2011

Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD

Resverlogix Corp. today announced that SUSTAIN, a Phase 2b clinical trial comprised of 176 subjects, is fully enrolled.

28 Nov 2011

Novel proteomics based method detects inhibition of intracellular deubiquitylating enzymes

Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled "Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes" that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs).

28 Nov 2011

New creative uses of DNA 'barcoding'

The newfound scientific power to quickly "fingerprint" species via DNA is being deployed to unmask quack herbal medicines, reveal types of ancient Arctic life frozen in permafrost, expose what eats what in nature, and halt agricultural and forestry pests at borders, among other applications across a wide array of public interests.

28 Nov 2011

Knocking out one copy of IGF1 receptor fails to increase life span of male mice

Scientists studying longevity thought it might be good to lack a copy of a gene, called IGF1 receptor, that is important in insulin signaling. Previous studies showed invertebrates that lacked the copy lived longer, even if their bodies were less responsive to insulin, the hormone that lowers blood sugar.

24 Nov 2011

Study reveals principal mechanism of action for paracetamol

Researchers at King's College London have discovered how one of the most common household painkillers works, which could pave the way for less harmful pain relief medications to be developed in the future.

23 Nov 2011

New procedure could be adapted for use with X-ray techniques in studying human health

For more than a century, the use of X-rays has been a prime diagnostic tool when it comes to human health. As it turns out, X-rays also are a crucial component for studying and understanding molecules, and a new approach -- just published by researchers at the University of Georgia -- may dramatically improve what researchers can learn using the technique.

23 Nov 2011

Scientists identify new immune system defect in aged mice

As people age, their immune system becomes less robust. This makes them more susceptible to serious and frequently life-threatening infections with viruses that affect the respiratory tract such as influenza A virus.

22 Nov 2011

New way to enhance effects of anandamide in the body

UC Irvine and Italian researchers have discovered a new means of enhancing the effects of anandamide - a natural, marijuana-like chemical in the body that provides pain relief.

22 Nov 2011

Researchers manipulate life span of yeast by mutating chemical residues

Collaborations between Johns Hopkins and National Taiwan University researchers have successfully manipulated the life span of common, single-celled yeast organisms by figuring out how to remove and restore protein functions related to yeast aging.

22 Nov 2011

Targeting synthetic RNA to specific gene could help reduce severity of SMA

A team of University of Missouri researchers have found that targeting a synthetic molecule to a specific gene could help the severity of the disease Spinal Muscular Atrophy (SMA) - the leading genetic cause of infantile death in the world.

22 Nov 2011

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Knopp Biosciences LLC today announced the publication in Nature Medicine of comprehensive results from the Phase 2 study of dexpramipexole, a small-molecule modulator of mitochondrial bioenergetics, in people with amyotrophic lateral sclerosis.

21 Nov 2011

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).

21 Nov 2011

New method for counting molecules

Researchers at the Swedish medical university Karolinska Institutet have developed a new method for counting molecules.

21 Nov 2011

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

21 Nov 2011

Scientists identify novel gene mutation that causes glioblastoma

Scientists at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center, in collaboration with colleagues in Boston and South Korea, say they have identified a novel gene mutation that causes at least one form of glioblastoma (GBM), the most common type of malignant brain tumor.

18 Nov 2011

Merrimack initiates MM-121 Phase 2 combination trial in metastatic NSCLC

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with erlotinib, a small molecule directed at the epidermal growth factor receptor (EGFR), in three groups of patients with metastatic non-small cell lung cancer.

18 Nov 2011

Dendrimers can capture circulating tumor cells in blood by biomimicry

The removal of rare tumor cells circulating in the blood might be possible with the use of biomolecules bound to dendrimers, highly branched synthetic polymers, which could efficiently sift and capture the diseased cells, according to new research at the University of Illinois at Chicago.

18 Nov 2011

First study to describe transporter system that bacteria use to ensure their survival

Bacteria responsible for middle ear infections, pink eye and sinusitis protect themselves from further immune attack by transporting molecules meant to destroy them away from their inner membrane target, according to a study from Nationwide Children's Hospital.

18 Nov 2011

Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial

The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva's Azilect, for the treatment of Parkinson's disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson's drug that has proven to have a disease-modifying effect. Novartis's Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer's disease.

17 Nov 2011